WO2008055047A2 - Devices and methods to simulate an ocular environment - Google Patents
Devices and methods to simulate an ocular environment Download PDFInfo
- Publication number
- WO2008055047A2 WO2008055047A2 PCT/US2007/082584 US2007082584W WO2008055047A2 WO 2008055047 A2 WO2008055047 A2 WO 2008055047A2 US 2007082584 W US2007082584 W US 2007082584W WO 2008055047 A2 WO2008055047 A2 WO 2008055047A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- testing surface
- male
- female
- concave
- testing
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 39
- 238000012360 testing method Methods 0.000 claims description 155
- -1 bisfilcon A Chemical compound 0.000 claims description 21
- 239000008177 pharmaceutical agent Substances 0.000 claims description 20
- 238000012544 monitoring process Methods 0.000 claims description 10
- MMWFQFGXFPTUIF-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one 2-hydroxyethyl 2-methylprop-2-enoate 2-(2-methylprop-2-enoyloxy)ethyl 2-methylprop-2-enoate prop-2-enyl 2-methylprop-2-enoate Chemical compound C=CN1CCCC1=O.CC(=C)C(=O)OCCO.CC(=C)C(=O)OCC=C.CC(=C)C(=O)OCCOC(=O)C(C)=C MMWFQFGXFPTUIF-UHFFFAOYSA-N 0.000 claims description 6
- UURVHRGPGCBHIC-UHFFFAOYSA-N 3-(ethenoxycarbonylamino)propanoic acid 4-[[[[[[[[[[[[[[[[[[[[[[[[[[[4-ethenoxycarbonyloxybutyl(dimethyl)silyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]butyl ethenyl carbonate 1-ethenylpyrrolidin-2-one ethenyl N-[3-tris(trimethylsilyloxy)silylpropyl]carbamate Chemical compound C=CN1CCCC1=O.OC(=O)CCNC(=O)OC=C.C[Si](C)(C)O[Si](CCCNC(=O)OC=C)(O[Si](C)(C)C)O[Si](C)(C)C.C[Si](C)(CCCCOC(=O)OC=C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)CCCCOC(=O)OC=C UURVHRGPGCBHIC-UHFFFAOYSA-N 0.000 claims description 4
- 229920001616 Polymacon Polymers 0.000 claims description 4
- NLAIHECABDOZBR-UHFFFAOYSA-M sodium 2,2-bis(2-methylprop-2-enoyloxymethyl)butyl 2-methylprop-2-enoate 2-hydroxyethyl 2-methylprop-2-enoate 2-methylprop-2-enoate Chemical compound [Na+].CC(=C)C([O-])=O.CC(=C)C(=O)OCCO.CCC(COC(=O)C(C)=C)(COC(=O)C(C)=C)COC(=O)C(C)=C NLAIHECABDOZBR-UHFFFAOYSA-M 0.000 claims description 4
- GNTAAQBKCCJXGF-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one methyl 2-methylprop-2-enoate 2-(2-methylprop-2-enoyloxy)ethyl 2-methylprop-2-enoate prop-2-enyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.C=CN1CCCC1=O.CC(=C)C(=O)OCC=C.CC(=C)C(=O)OCCOC(=O)C(C)=C GNTAAQBKCCJXGF-UHFFFAOYSA-N 0.000 claims description 3
- SVKHOOHZPMBIGM-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;2-hydroxyethyl 2-methylprop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.C=CN1CCCC1=O.CC(=C)C(=O)OCCO SVKHOOHZPMBIGM-UHFFFAOYSA-N 0.000 claims description 3
- XPSXBEJFSQZTBS-UHFFFAOYSA-N 2,2-bis(2-methylprop-2-enoyloxymethyl)butyl 2-methylprop-2-enoate 2-hydroxyethyl 2-methylprop-2-enoate N-(2-methyl-4-oxopentan-2-yl)prop-2-enamide Chemical compound CC(=C)C(=O)OCCO.CC(=O)CC(C)(C)NC(=O)C=C.CCC(COC(=O)C(C)=C)(COC(=O)C(C)=C)COC(=O)C(C)=C XPSXBEJFSQZTBS-UHFFFAOYSA-N 0.000 claims description 3
- KKOWZRLUUCIGQY-UHFFFAOYSA-N 2-hydroxyethyl 2-methylprop-2-enoate 2-methylprop-2-enoic acid 2-(2-methylprop-2-enoyloxy)ethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(O)=O.CC(=C)C(=O)OCCO.CC(=C)C(=O)OCCOC(=O)C(C)=C KKOWZRLUUCIGQY-UHFFFAOYSA-N 0.000 claims description 3
- PVISMVGVPWOQMG-UHFFFAOYSA-N 2-hydroxyethyl 2-methylprop-2-enoate;2-(2-methylprop-2-enoyloxy)ethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCO.CC(=C)C(=O)OCCOC(=O)C(C)=C PVISMVGVPWOQMG-UHFFFAOYSA-N 0.000 claims description 3
- 238000009792 diffusion process Methods 0.000 claims description 2
- 238000010998 test method Methods 0.000 claims description 2
- 239000000243 solution Substances 0.000 description 33
- 239000003795 chemical substances by application Substances 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- 239000000203 mixture Substances 0.000 description 5
- 235000002639 sodium chloride Nutrition 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- ZZHLYYDVIOPZBE-UHFFFAOYSA-N Trimeprazine Chemical compound C1=CC=C2N(CC(CN(C)C)C)C3=CC=CC=C3SC2=C1 ZZHLYYDVIOPZBE-UHFFFAOYSA-N 0.000 description 4
- 230000003278 mimic effect Effects 0.000 description 4
- WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000008366 buffered solution Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229960003630 ketotifen fumarate Drugs 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- SFOVDSLXFUGAIV-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]-n-piperidin-4-ylbenzimidazol-2-amine Chemical compound C1=CC(F)=CC=C1CN1C2=CC=CC=C2N=C1NC1CCNCC1 SFOVDSLXFUGAIV-UHFFFAOYSA-N 0.000 description 2
- CNIIGCLFLJGOGP-UHFFFAOYSA-N 2-(1-naphthalenylmethyl)-4,5-dihydro-1H-imidazole Chemical compound C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 description 2
- QSAVEGSLJISCDF-UHFFFAOYSA-N 2-hydroxy-2-phenylacetic acid (1,2,2,6-tetramethyl-4-piperidinyl) ester Chemical compound C1C(C)(C)N(C)C(C)CC1OC(=O)C(O)C1=CC=CC=C1 QSAVEGSLJISCDF-UHFFFAOYSA-N 0.000 description 2
- USCSJAIWXWYTEH-UHFFFAOYSA-N 7-[3-[4-[(4-chlorophenyl)methyl]piperazin-1-yl]propoxy]-3,4-dimethylchromen-2-one Chemical compound C1=CC=2C(C)=C(C)C(=O)OC=2C=C1OCCCN(CC1)CCN1CC1=CC=C(Cl)C=C1 USCSJAIWXWYTEH-UHFFFAOYSA-N 0.000 description 2
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 2
- MBUVEWMHONZEQD-UHFFFAOYSA-N Azeptin Chemical compound C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 MBUVEWMHONZEQD-UHFFFAOYSA-N 0.000 description 2
- ZTVIKZXZYLEVOL-MCOXGKPRSA-N Homatropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(O)C1=CC=CC=C1 ZTVIKZXZYLEVOL-MCOXGKPRSA-N 0.000 description 2
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 2
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 2
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 2
- OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 description 2
- HOKDBMAJZXIPGC-UHFFFAOYSA-N Mequitazine Chemical compound C12=CC=CC=C2SC2=CC=CC=C2N1CC1C(CC2)CCN2C1 HOKDBMAJZXIPGC-UHFFFAOYSA-N 0.000 description 2
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 2
- 229960003790 alimemazine Drugs 0.000 description 2
- 229960002469 antazoline Drugs 0.000 description 2
- REYFJDPCWQRWAA-UHFFFAOYSA-N antazoline Chemical compound N=1CCNC=1CN(C=1C=CC=CC=1)CC1=CC=CC=C1 REYFJDPCWQRWAA-UHFFFAOYSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- GXDALQBWZGODGZ-UHFFFAOYSA-N astemizole Chemical compound C1=CC(OC)=CC=C1CCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2C=CC(F)=CC=2)CC1 GXDALQBWZGODGZ-UHFFFAOYSA-N 0.000 description 2
- 229960000383 azatadine Drugs 0.000 description 2
- SEBMTIQKRHYNIT-UHFFFAOYSA-N azatadine Chemical compound C1CN(C)CCC1=C1C2=NC=CC=C2CCC2=CC=CC=C21 SEBMTIQKRHYNIT-UHFFFAOYSA-N 0.000 description 2
- 229960004574 azelastine Drugs 0.000 description 2
- 229960002881 clemastine Drugs 0.000 description 2
- YNNUSGIPVFPVBX-NHCUHLMSSA-N clemastine Chemical compound CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-NHCUHLMSSA-N 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 229960001140 cyproheptadine Drugs 0.000 description 2
- JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 description 2
- 229960001971 ebastine Drugs 0.000 description 2
- MJJALKDDGIKVBE-UHFFFAOYSA-N ebastine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)CCCN1CCC(OC(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 MJJALKDDGIKVBE-UHFFFAOYSA-N 0.000 description 2
- 229960000325 emedastine Drugs 0.000 description 2
- KBUZBQVCBVDWKX-UHFFFAOYSA-N emedastine Chemical compound N=1C2=CC=CC=C2N(CCOCC)C=1N1CCCN(C)CC1 KBUZBQVCBVDWKX-UHFFFAOYSA-N 0.000 description 2
- 229950002420 eucatropine Drugs 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- 229960003592 fexofenadine Drugs 0.000 description 2
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229960000857 homatropine Drugs 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 229960000930 hydroxyzine Drugs 0.000 description 2
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 2
- 229960004958 ketotifen Drugs 0.000 description 2
- YNQQEYBLVYAWNX-WLHGVMLRSA-N ketotifen fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 YNQQEYBLVYAWNX-WLHGVMLRSA-N 0.000 description 2
- 229960001120 levocabastine Drugs 0.000 description 2
- ZCGOMHNNNFPNMX-KYTRFIICSA-N levocabastine Chemical compound C1([C@@]2(C(O)=O)CCN(C[C@H]2C)[C@@H]2CC[C@@](CC2)(C#N)C=2C=CC(F)=CC=2)=CC=CC=C1 ZCGOMHNNNFPNMX-KYTRFIICSA-N 0.000 description 2
- 229960001474 meclozine Drugs 0.000 description 2
- 229960005042 mequitazine Drugs 0.000 description 2
- 229960001869 methapyrilene Drugs 0.000 description 2
- HNJJXZKZRAWDPF-UHFFFAOYSA-N methapyrilene Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CS1 HNJJXZKZRAWDPF-UHFFFAOYSA-N 0.000 description 2
- 239000002637 mydriatic agent Substances 0.000 description 2
- 230000002911 mydriatic effect Effects 0.000 description 2
- 235000021436 nutraceutical agent Nutrition 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 229960001528 oxymetazoline Drugs 0.000 description 2
- 229950010674 picumast Drugs 0.000 description 2
- 229960003910 promethazine Drugs 0.000 description 2
- 229960002646 scopolamine Drugs 0.000 description 2
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229960000351 terfenadine Drugs 0.000 description 2
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 2
- 229960001128 triprolidine Drugs 0.000 description 2
- CBEQULMOCCWAQT-WOJGMQOQSA-N triprolidine Chemical compound C1=CC(C)=CC=C1C(\C=1N=CC=CC=1)=C/CN1CCCC1 CBEQULMOCCWAQT-WOJGMQOQSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 1
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
- RLKDAQKJMRBCEU-UHFFFAOYSA-N 1h-1-benzazepine-3-carbaldehyde Chemical compound C1=CC(C=O)=CNC2=CC=CC=C21 RLKDAQKJMRBCEU-UHFFFAOYSA-N 0.000 description 1
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 1
- WSSSPWUEQFSQQG-UHFFFAOYSA-N 4-methyl-1-pentene Chemical compound CC(C)CC=C WSSSPWUEQFSQQG-UHFFFAOYSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000004812 Fluorinated ethylene propylene Substances 0.000 description 1
- UEQUQVLFIPOEMF-UHFFFAOYSA-N Mianserin Chemical compound C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 UEQUQVLFIPOEMF-UHFFFAOYSA-N 0.000 description 1
- IJHNSHDBIRRJRN-UHFFFAOYSA-N N,N-dimethyl-3-phenyl-3-(2-pyridinyl)-1-propanamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=CC=C1 IJHNSHDBIRRJRN-UHFFFAOYSA-N 0.000 description 1
- IYSYPCSSDZBWHN-UHFFFAOYSA-N Nor-ketotifen Chemical compound C1=2C=CSC=2C(=O)CC2=CC=CC=C2C1=C1CCNCC1 IYSYPCSSDZBWHN-UHFFFAOYSA-N 0.000 description 1
- PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 description 1
- 229930182556 Polyacetal Natural products 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 1
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 230000000964 angiostatic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940127090 anticoagulant agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 229960001705 buclizine Drugs 0.000 description 1
- MOYGZHXDRJNJEP-UHFFFAOYSA-N buclizine Chemical compound C1=CC(C(C)(C)C)=CC=C1CN1CCN(C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1 MOYGZHXDRJNJEP-UHFFFAOYSA-N 0.000 description 1
- 229960003150 bupivacaine Drugs 0.000 description 1
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 1
- 229960001803 cetirizine Drugs 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 229960003564 cyclizine Drugs 0.000 description 1
- UVKZSORBKUEBAZ-UHFFFAOYSA-N cyclizine Chemical compound C1CN(C)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 UVKZSORBKUEBAZ-UHFFFAOYSA-N 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- HQQADJVZYDDRJT-UHFFFAOYSA-N ethene;prop-1-ene Chemical group C=C.CC=C HQQADJVZYDDRJT-UHFFFAOYSA-N 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 229960002422 lomefloxacin Drugs 0.000 description 1
- ZEKZLJVOYLTDKK-UHFFFAOYSA-N lomefloxacin Chemical compound FC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1 ZEKZLJVOYLTDKK-UHFFFAOYSA-N 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960002409 mepivacaine Drugs 0.000 description 1
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 description 1
- 229960004056 methdilazine Drugs 0.000 description 1
- HTMIBDQKFHUPSX-UHFFFAOYSA-N methdilazine Chemical compound C1N(C)CCC1CN1C2=CC=CC=C2SC2=CC=CC=C21 HTMIBDQKFHUPSX-UHFFFAOYSA-N 0.000 description 1
- 229960003955 mianserin Drugs 0.000 description 1
- 230000003547 miosis Effects 0.000 description 1
- 239000003604 miotic agent Substances 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 229960005016 naphazoline Drugs 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 1
- 229940033080 omega-6 fatty acid Drugs 0.000 description 1
- 239000002997 ophthalmic solution Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229920009441 perflouroethylene propylene Polymers 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960001190 pheniramine Drugs 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 description 1
- 229960001697 physostigmine Drugs 0.000 description 1
- 229920000110 poly(aryl ether sulfone) Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000002294 steroidal antiinflammatory agent Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003856 thermoforming Methods 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 239000012815 thermoplastic material Substances 0.000 description 1
- 229920002397 thermoplastic olefin Polymers 0.000 description 1
- 229920005992 thermoplastic resin Polymers 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- 229960004869 thiethylperazine Drugs 0.000 description 1
- XCTYLCDETUVOIP-UHFFFAOYSA-N thiethylperazine Chemical compound C12=CC(SCC)=CC=C2SC2=CC=CC=C2N1CCCN1CCN(C)CC1 XCTYLCDETUVOIP-UHFFFAOYSA-N 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 229960004605 timolol Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
- 235000010930 zeaxanthin Nutrition 0.000 description 1
- 239000001775 zeaxanthin Substances 0.000 description 1
- 229940043269 zeaxanthin Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N13/00—Investigating surface or boundary effects, e.g. wetting power; Investigating diffusion effects; Analysing materials by determining surface, boundary, or diffusion effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01M—TESTING STATIC OR DYNAMIC BALANCE OF MACHINES OR STRUCTURES; TESTING OF STRUCTURES OR APPARATUS, NOT OTHERWISE PROVIDED FOR
- G01M11/00—Testing of optical apparatus; Testing structures by optical methods not otherwise provided for
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/02—Investigating particle size or size distribution
-
- G—PHYSICS
- G02—OPTICS
- G02C—SPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES
- G02C7/00—Optical parts
- G02C7/02—Lenses; Lens systems ; Methods of designing lenses
- G02C7/04—Contact lenses for the eyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N13/00—Investigating surface or boundary effects, e.g. wetting power; Investigating diffusion effects; Analysing materials by determining surface, boundary, or diffusion effects
- G01N2013/006—Dissolution of tablets or the like
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/44—Resins; Plastics; Rubber; Leather
- G01N33/442—Resins; Plastics
Definitions
- This invention related to devices and methods simulate an ocular environment to enable the testing of ophthalmic lens.
- BACKGROUND Most diseases of the eye are treated with topical ophthalmic solutions containing pharmaceutical agents. It has been postulated that delivery and efficacy of these agents would be greatly increased if the agents were incorporated in ophthalmic lenses and those lenses were used as drug delivery devices. These agents may be added to the ophthalmic lenses by a variety of methods including soaking the agent into a formed lens, adding the agent to the formulation of the lens prior to its formation and the like. Others have postulated methods of testing the uptake and discharge rates of such pharmaceutical agents to and from the ophthalmic lenses. These methods include placing ophthalmic lenses in solutions and monitoring the concentration of the pharmaceutical agent over time. Even though these methods work, due to the volume of solution used in the test, the conditions do not mimic the conditions that an ophthalmic lens is exposed to when inserted into an ocular environment.
- Fig. 1 illustrates a perspective drawing of a male mold.
- Fig. 2 illustrates a perspective drawing of a female mold.
- Fig. 3 illustrates a close up cross-sectional drawing of the mated apparatus.
- Fig. 4 illustrates a perspective drawing of a male mold.
- Fig. 5 illustrates a perspective drawing of a female mold.
- Fig. 6 illustrates a cross-sectional drawing of the mated apparatus.
- Fig. 7 illustrates a close up cross-sectional drawing of the mated apparatus.
- This invention includes an apparatus for testing an ophthalmic lens comprising a male mold and a female mold, wherein said male mold comprises a convex testing surface, an outer male surface, male seating ridge extending from the perimeter of the convex testing surface, and an aperture extending from said outer male surface to said convex testing surface,
- said female mold comprises an outer female surface a concave testing surface, female seating ridge extending from the perimeter of the concave testing surface, and an aperture extending from said concave testing surface to said outer female surface,
- the male seating ridge sits on the female seating ridge and creates a testing area between the male convex testing surface and the female concave testing surface.
- Fig. 1 a perspective drawing of a male mold 100, contains convex testing surface 120, aperture 160, and, male seating ridge 180.
- Fig. 2 a perspective drawing of a female mold 200, contains concave testing surface 220, aperture 260, and female seating ridge 280.
- Fig. 3 a close up cross section of mated apparatus, where the mated convex testing surface 120 and concave testing surface 220, define the testing area 300 between those surfaces.
- the convex and concave testing surfaces are of a size and shape to mimic the shape of the eye and an eyelid. Testing area 300 is large enough to hold an ophthalmic lens (not shown) and a volume of solution.
- the testing area be sized to house an ophthalmic lens and about 50 ⁇ l_ to about 500 ⁇ l_ of solution, more preferably, about 100 ⁇ l_ to about 400 ⁇ l_ of solution, most preferably about 200 ⁇ l_ of solution.
- the convex or concave testing surfaces of the apparatus may contain grooves that provide pathways for the small volumes of solutions to pass over the surfaces of ophthalmic lenses contained in the testing area. These grooves may be in any number or orientation, but preferably a convex or concave testing surface contains at least one latitudinal groove and one radial groove. It is preferred that such grooves intersect at a point on the convex or concave testing surface.
- both the concave and the convex surfaces contain radial and latitudinal grooves.
- Fig. 4 a perspective drawing of a male mold 10, contains convex testing surface Yl, four radial grooves 14, aperture 16, male seating ridge 18, and six concentric latitudinal grooves 19.
- Fig. 5, a perspective drawing of a female mold 20, contains concave testing surface 22, four radial grooves, 24, aperture 26, female seating ridge 28, and nine concentric latitudinal grooves 29.
- the radial grooves on the convex testing surface intersect with the latitudinal grooves so as to allow solutions that flow through the apertures, to more easily flow to the entire convex testing surface.
- each testing surface may contain the same or different numbers of radial grooves. It is preferred that each testing surface contain contains at least two radial grooves, more preferably three radial grooves, most preferably four radial grooves. With respect to latitudinal grooves, the number of these grooves on each testing surface may be the same or different. It is preferred that each testing surface contain contains at least four latitudinal grooves, more preferably at least five latitudinal grooves, most preferably at least eight latitudinal grooves.
- the outer male and female surfaces may be the same or different shapes. In one embodiment of the invention (not illustrated) the outer male surface is concave and the outer female surface is convex.
- the convex and concave testing surfaces are of a size and shape to mimics the shape of an eye and an eyelid.
- Fig. 6 a cross section of the mated apparatus, with male mold 10, female mold 20, male outer surface 13, female outer surface 23, male seating ridge 18, and female seating ridge 28.
- aperture 16 extends from male outer surface 13 to the convex testing surface 12 to the testing area not shown.
- aperture 26 extends from concave testing surface 22 to outer female surface 23.
- Fig. 7 a close up cross section of mated apparatus, where the mated convex testing surface Y ⁇ and concave testing surface 22, define the testing area 30 those surfaces.
- Testing area 30 is large enough to hold an ophthalmic lens (not shown) and a volume of solution. It is preferred that the testing area be sized to house an ophthalmic lens and about 50 ⁇ l_ to about 500 ⁇ l_ of solution, more preferably, about 100 ⁇ l_ to about 400 ⁇ l_ of solution, most preferably about 200 ⁇ l_ of solution.
- the apparatus of the invention may be prepared from durable thermoplastic materials, such as thermoplastic resins, polyolefins, and thermoplastic polyesters.
- durable thermoplastic materials such as thermoplastic resins, polyolefins, and thermoplastic polyesters.
- thermoplastic resins such as thermoplastic resins, polyolefins, and thermoplastic polyesters.
- materials include but are not limited to low medium, medium and high density polypropylene, polyethylene and co-polymers thereof, poly-4-methylpentene, fluorinated ethylene propylene copolymers, ethylene fluoroethylene copolymers, polyacetal resins, polacrylether, polyarylether sulfones, nylons, and the like.
- the apparatus may be prepared by injection molding thermoforming and the like.
- the invention includes a method of testing the diffusion rate of an ophthalmic device comprising a pharmaceutical agent, wherein the method comprises the steps of (a) placing an ophthalmic lens comprising a pharmaceutical agent in the testing area of an apparatus comprising a male mold and a female mold,
- said male mold comprises a convex testing surface an outer male surface, male seating ridge extending from the perimeter of the convex testing surface, and an aperture extending from said outer male surface to said convex testing surface,
- said female mold comprises an outer female surface a concave testing surface, female seating ridge extending from the perimeter of the concave testing surface, and an aperture extending from said concave testing surface to said outer female surface,
- the male seating ridge sits on the female seating ridge and creates a testing area between the male convex testing surface and the female concave testing surface.
- male mold female mold, radial groove, latitudinal groove, testing area convex testing surface, and concave testing surface are as described above.
- pharmaceutical agents refers to pharmaceutical or nutraceutical compounds used to treat conditions of the eye, and such compound degrade in the presence of oxygen and certain transition metals.
- pharmaceutical compounds include antihistamines, antibiotics, antibacterial agents, antiviral agents, antifungal agents, analgesics, anesthetics, antiallergeneic agents, mast cell stabilizers, steroidal and nonsteroidal anti-inflammatory agents, angiogenesis inhibitors; antimetabolites, fibrinolytics, neuroprotective drugs, angiostatic steroids, mydriatics, cyclopegic mydriatics; miotics; vasoconstrictors; vasodilators, anticlotting agents; anticancer agents, antisense agents, immunomodulatory agents, carbonic anhydrase inhibitors, integhn antabonistsl; cyclooxygenase inhibitors, VEGF antagonists; immunosuppressant agents and the like.
- examples of pharmaceutical compounds include but are not limited to achvastine, antazoline, astemizole, azatadine, azelastine, buclizine, bupivacaine, cetirizine, clemastine, cyclizine, cyproheptadine, ebastine, emedastine, ephedrine, eucatropine, fexofenadine, homatropine, hydroxyzine, ketotifen, levocabastine, levoceterizine, lomefloxacin, meclizine, mepivacaine, mequitazine, methdilazine, methapyrilene, mianserin, naphazoline norastemizole, norebastine, ofloxacin, oxymetazoline, pheniramine, phenylephrine, physostigmine, picumast, promethazine, scopolamine, terfen
- Preferred pharmaceutical compounds include achvatine, antazoline, astemizole, azatadine, azelastine, clemastine, cyproheptadine, ebastine, emedastine, eucatropine, fexofenadine, homatropine, hydroxyzine, ketotife, levocabastine, levoceterizine, meclizine, mequitazine, methdialazine, methapyrilene, norastemizole, norebastine, oxymetazoline, physootigmine, picumast, promethazine, scopolamine, terfenadine, tetrahyerozoline, fimilol, trimeprazine, triprolidine, and pharmaceutically acceptable salts thereof.
- Particularly preferred pharmaceutical compounds include phenarimine, ketotifen, ketotifen fumarate nor ketotifen fumarate, 11 -dihydro-11 -(1 -methyl-4-piperidinylidene)- 5H-imidazo[2,1 -b][3]benzazepine-3-carboxaldehyde (CAS# 147084-10-4), olapatadine and mixtures thereof. More particularly preferred pharmaceutical compounds include ketotifen fumarate, 11 -dihydro-11 -(1 -methyl-4- pipehdinylidene)-5H-imidazo[2,1 -b][3]benzazepine-3-carboxaldehyde (CAS# 147084-10-4) and mixtures thereof.
- nutraceutical compounds include vitamins and supplements such as vitamins A, D, E, lutein, zeaxanthin, lipoic acid, flavonoids, ophthalmicially compatible fatty acids, such as omega 3 and omega 6 fatty acids, combinations thereof, combinations with pharmaceutical compounds and the like.
- the methods of the invention may be used to detect the discharge rate (or uptake rate) of ophthalmic lenses containing about 8 ⁇ g or more of pharmaceutical agent.
- the discharge rate for ophthalmic lenses that contain about 8 ⁇ g to about 90 ⁇ g, more preferably about 10 ⁇ g to about 40 ⁇ g, more preferably about 10 ⁇ g to about 25 ⁇ g may be determined by the methods of this invention.
- Ophthalmic lens refers to a device that resides in or on the eye. These devices can provide optical correction or may be cosmetic. Ophthalmic lenses include but are not limited to soft contact lenses, intraocular lenses, overlay lenses, ocular inserts, and optical inserts.
- the preferred lenses of the invention are soft contact lenses made from silicone elastomers or hydrogels, which include but are not limited to silicone hydrogels, and fluorohydrogels.
- Soft contact lens formulations are disclosed in US Patent No. 5,710,302, WO 9421698, EP 406161 , JP 2000016905, U.S. Pat. No. 5,998,498, U.S. Patent No. 6,087,415, U.S. Pat. No. 5,760,100, U.S. Pat.
- the particularly preferred ophthalmic lenses of the inventions are known by the United States Approved Names of acofilcon A, alofilcon A, alphafilcon A, amifilcon A, astifilcon A, atalafilcon A, balafilcon A, bisfilcon A, bufilcon A, comfilcon, crofilcon A, cyclofilcon A,balilcon A, deltafilcon A, deltafilcon B, dimefilcon A, drooxifilcon A, epsifilcon A, esterifilcon A, etafilcon A, focofilcon A, genfilcon A, govafilcon A, hefilcon A, hefilcon B, hefilcon D, hilafilcon A, hilafilcon B, hioxifilcon B, hioxifilcon C, hixoifilcon A, hydrofilcon A, lenefilcon A, licryfilcon A, licryfilcon B, lidofilcon A, lidofil
- More particularly preferred ophthalmic lenses of the invention are genfilcon A, lenefilcon A, comfilcon, lotrafilcon A, lotraifilcon B, and balafilcon A.
- the most preferred lenses include etafilcon A, nelfilcon A, hilafilcon, vifilcon, and polymacon.
- solutions that are used in methods of this invention may be water- based solutions. Solutions that mimic natural tear film are preferred. Typical solutions include, without limitation, saline solutions, other buffered solutions, and deionized water.
- the preferred aqueous solution is deioinized water or saline solution containing salts including, without limitation, sodium chloride, sodium borate, sodium phosphate, sodium hydrogenphosphate, sodium dihydrogenphosphate, or the corresponding potassium salts of the same.
- salts including, without limitation, sodium chloride, sodium borate, sodium phosphate, sodium hydrogenphosphate, sodium dihydrogenphosphate, or the corresponding potassium salts of the same.
- the buffered solutions may additionally include 2-(N-morpholino)ethanesulfonic acid (MES), sodium hydroxide, 2,2-bis(hydroxymethyl)-2,2',2"-nitnlothethanol, n-tris(hydroxynnethyl)nnethyl-2-anninoethanesulfonic acid, citric acid, sodium citrate, sodium carbonate, sodium bicarbonate, acetic acid, sodium acetate, ethylenediamine tetraacetic acid and the like and combinations thereof.
- MES 2-(N-morpholino)ethanesulfonic acid
- sodium hydroxide 2,2-bis(hydroxymethyl)-2,2',2"-nitnlothethanol
- n-tris(hydroxynnethyl)nnethyl-2-anninoethanesulfonic acid citric acid, sodium citrate, sodium carbonate, sodium bicarbonate, acetic acid, sodium acetate, ethylenediamine tetraacetic acid and the like
- monitoring refers to methods of analyzing the solution to determine the concentration of pharmaceutical agent in the solution. Examples of such detecting methods include but are not limited to HPLC, UV Spectormeters and the like. Still further the invention includes, a method of measuring the uptake rate of a pharmaceutical agent to an ophthalmic lens, wherein the method comprises the steps of
- said female mold comprises an outer female surface a concave testing surface, female seating ridge extending from the perimeter of the concave testing surface, and an aperture extending from said concave testing surface to said outer female surface,
- the male seating ridge sits on the female seating ridge and creates a testing area between the male convex testing surface and the female concave testing surface.
- male mold female mold, radial groove, latitudinal groove, testing area convex testing surface, concave testing surface, pharmaceutical agent, ophthalmic lens, solution and monitoring are as described above.
- this invention includes a method of measuring the uptake rate of an eyecare solution component to an ophthalmic lens, wherein the method comprises the steps of
- said female mold comprises an outer female surface a concave testing surface, female seating ridge extending from the perimeter of the concave testing surface, and an aperture extending from said concave testing surface to said outer female surface,
- the male seating ridge sits on the female seating ridge and creates a testing area between the male convex testing surface and the female concave testing surface, (b) adding a solution comprising eyecare solution components to the aperture of the male mold from the outer male surface, and (c) monitoring the solution that emerges from the aperture of the outer female surface to determine the presence or absence of the eyecare solution component.
- male mold female mold, radial groove, latitudinal groove, testing area convex testing surface, concave testing surface, eyecare solution component, ophthalmic lens, solution and monitoring are as described above.
Landscapes
- Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Optics & Photonics (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Dispersion Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Eyeglasses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Eye Examination Apparatus (AREA)
- Materials For Medical Uses (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Instructional Devices (AREA)
- Prostheses (AREA)
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2007313797A AU2007313797A1 (en) | 2006-10-31 | 2007-10-26 | Devices and methods to simulate an ocular environment |
EP07854430.1A EP2078186B1 (en) | 2006-10-31 | 2007-10-26 | Devices and methods to simulate an ocular environment |
CA2668296A CA2668296C (en) | 2006-10-31 | 2007-10-26 | Devices and methods to simulate an ocular environment |
CN2007800489590A CN101573604B (zh) | 2006-10-31 | 2007-10-26 | 模拟眼环境的装置和方法 |
JP2009535401A JP2010508562A (ja) | 2006-10-31 | 2007-10-26 | 眼環境をシミュレーションするための装置および方法 |
BRPI0718298-8A BRPI0718298A2 (pt) | 2006-10-31 | 2007-10-26 | Dispositivos e métodos para simular um ambiente ocular |
HK09111019.5A HK1133297A1 (zh) | 2006-10-31 | 2009-11-25 | 模擬眼環境的裝置和方法 |
HK10104340.7A HK1138640A1 (zh) | 2006-10-31 | 2010-05-03 | 模擬眼環境的裝置和方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US85543306P | 2006-10-31 | 2006-10-31 | |
US60/855,433 | 2006-10-31 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008055047A2 true WO2008055047A2 (en) | 2008-05-08 |
WO2008055047A3 WO2008055047A3 (en) | 2008-06-26 |
Family
ID=39154017
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/082584 WO2008055047A2 (en) | 2006-10-31 | 2007-10-26 | Devices and methods to simulate an ocular environment |
Country Status (13)
Country | Link |
---|---|
US (2) | US7793535B2 (zh) |
EP (1) | EP2078186B1 (zh) |
JP (1) | JP2010508562A (zh) |
KR (1) | KR20090094816A (zh) |
CN (1) | CN101573604B (zh) |
AR (1) | AR063753A1 (zh) |
AU (1) | AU2007313797A1 (zh) |
BR (1) | BRPI0718298A2 (zh) |
CA (1) | CA2668296C (zh) |
HK (2) | HK1133297A1 (zh) |
RU (1) | RU2443999C2 (zh) |
TW (1) | TWI460417B (zh) |
WO (1) | WO2008055047A2 (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2083793A2 (en) * | 2006-10-31 | 2009-08-05 | Johnson and Johnson Vision Care, Inc. | Methods and devices to test diffusion rates of ocular drug delivery systems |
US7968018B2 (en) * | 2007-04-18 | 2011-06-28 | Coopervision International Holding Company, Lp | Use of surfactants in extraction procedures for silicone hydrogel ophthalmic lenses |
US8295684B2 (en) * | 2007-10-08 | 2012-10-23 | Sony Computer Entertainment America Inc. | Method and system for scaling content for playback with variable duration |
US9827250B2 (en) | 2012-07-31 | 2017-11-28 | Johnson & Johnson Vision Care, Inc. | Lens incorporating myopia control optics and muscarinic agents |
US9069186B2 (en) * | 2013-03-15 | 2015-06-30 | Johnson & Johnson Vision Care, Inc. | Thermoformed ophthalmic insert devices |
KR20200048825A (ko) * | 2018-10-30 | 2020-05-08 | 부산대학교 산학협력단 | 가상현실 기반의 백내장 수술 시뮬레이터 시스템 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0406161A2 (en) | 1989-06-20 | 1991-01-02 | Ciba-Geigy Ag | Fluorine and/or silicone containing poly(alkylene-oxide)-block copolymers and contact lenses thereof |
WO1994021698A1 (en) | 1993-03-15 | 1994-09-29 | Bausch & Lomb Incorporated | Novel fumarate and fumaramide siloxane hydrogel compositions |
US5710302A (en) | 1995-12-07 | 1998-01-20 | Bausch & Lomb Incorporated | Monomeric units useful for reducing the modules of silicone hydrogels |
US5760100A (en) | 1994-09-06 | 1998-06-02 | Ciba Vision Corporation | Extended wear ophthalmic lens |
US5776999A (en) | 1994-09-06 | 1998-07-07 | Ciba Vision Corporation | Methods of using and screening extended wear ophthalmic lenses |
US5817924A (en) | 1998-01-21 | 1998-10-06 | Modern Controls, Inc. | Method and apparatus for measuring oxygen transmission through contact lenses |
US5998498A (en) | 1998-03-02 | 1999-12-07 | Johnson & Johnson Vision Products, Inc. | Soft contact lenses |
JP2000016905A (ja) | 1998-07-01 | 2000-01-18 | Tokuriki Kagaku Kenkyusho:Kk | 抗菌抗かび剤および抗菌抗かび材料 |
US6087415A (en) | 1998-06-11 | 2000-07-11 | Johnson & Johnson Vision Care, Inc. | Biomedical devices with hydrophilic coatings |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8601967D0 (en) * | 1986-01-28 | 1986-03-05 | Coopervision Optics | Manufacturing contact lenses |
US4782946A (en) * | 1987-09-17 | 1988-11-08 | Allergan, Inc. | Soft contact lens hydration device and kit |
TW325744U (en) * | 1993-07-21 | 1998-01-21 | Ciba Geigy Ag | Two-sided contact lens mold |
US5490415A (en) * | 1994-04-15 | 1996-02-13 | Pharmetrix Corporation | Diffusion test apparatus and method |
JP3813667B2 (ja) | 1996-09-24 | 2006-08-23 | 株式会社トーメー | コンタクトレンズ用洗浄・消毒用具及びそれを用いたコンタクトレンズの消毒方法 |
US6450014B1 (en) * | 1999-12-28 | 2002-09-17 | Eastman Kodak Company | Method and apparatus for measuring osmotic pressure |
ATE310634T1 (de) * | 2001-05-23 | 2005-12-15 | Novartis Pharma Gmbh | Aufnahmekorb für eine ophtalmische linse |
US6909503B2 (en) * | 2001-08-17 | 2005-06-21 | Novartis Ag | Cuvette for lens inspection |
DE60326597D1 (de) | 2002-06-05 | 2009-04-23 | Univ Florida | Ophthalmisches arzneimittelabgabesystem |
US6981403B2 (en) * | 2003-10-31 | 2006-01-03 | Mocon, Inc. | Method and apparatus for measuring gas transmission rates of deformable or brittle materials |
CA2597219C (en) * | 2005-02-04 | 2014-04-15 | Auburn University | Contact drug delivery system |
SG177132A1 (en) * | 2005-02-14 | 2012-01-30 | Johnson & Johnson Vision Care | A comfortable ophthalmic device and methods of its production |
EP2083793A2 (en) * | 2006-10-31 | 2009-08-05 | Johnson and Johnson Vision Care, Inc. | Methods and devices to test diffusion rates of ocular drug delivery systems |
-
2007
- 2007-10-25 US US11/923,680 patent/US7793535B2/en active Active
- 2007-10-26 WO PCT/US2007/082584 patent/WO2008055047A2/en active Application Filing
- 2007-10-26 BR BRPI0718298-8A patent/BRPI0718298A2/pt not_active IP Right Cessation
- 2007-10-26 EP EP07854430.1A patent/EP2078186B1/en not_active Not-in-force
- 2007-10-26 CA CA2668296A patent/CA2668296C/en not_active Expired - Fee Related
- 2007-10-26 KR KR1020097011210A patent/KR20090094816A/ko not_active Application Discontinuation
- 2007-10-26 RU RU2009120559/28A patent/RU2443999C2/ru not_active IP Right Cessation
- 2007-10-26 AU AU2007313797A patent/AU2007313797A1/en not_active Abandoned
- 2007-10-26 JP JP2009535401A patent/JP2010508562A/ja active Pending
- 2007-10-26 CN CN2007800489590A patent/CN101573604B/zh not_active Expired - Fee Related
- 2007-10-30 TW TW096140679A patent/TWI460417B/zh active
- 2007-10-31 AR ARP070104839A patent/AR063753A1/es not_active Application Discontinuation
-
2009
- 2009-11-25 HK HK09111019.5A patent/HK1133297A1/zh not_active IP Right Cessation
-
2010
- 2010-05-03 HK HK10104340.7A patent/HK1138640A1/zh not_active IP Right Cessation
- 2010-08-05 US US12/851,434 patent/US20100300182A1/en not_active Abandoned
Patent Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0406161A2 (en) | 1989-06-20 | 1991-01-02 | Ciba-Geigy Ag | Fluorine and/or silicone containing poly(alkylene-oxide)-block copolymers and contact lenses thereof |
WO1994021698A1 (en) | 1993-03-15 | 1994-09-29 | Bausch & Lomb Incorporated | Novel fumarate and fumaramide siloxane hydrogel compositions |
US5965631A (en) | 1994-09-06 | 1999-10-12 | Ciba Vision Corporation | Extended wear ophthalmic lens |
US5849811B1 (en) | 1994-09-06 | 2000-11-14 | Ciba Vision Corporatin | Extended wear ophthalmic lens |
US5776999A (en) | 1994-09-06 | 1998-07-07 | Ciba Vision Corporation | Methods of using and screening extended wear ophthalmic lenses |
US5789461A (en) | 1994-09-06 | 1998-08-04 | Ciba Vision Corporation | Methods of forming an extended wear ophthalmic lens having a hydrophilic surface |
US5760100A (en) | 1994-09-06 | 1998-06-02 | Ciba Vision Corporation | Extended wear ophthalmic lens |
US5849811A (en) | 1994-09-06 | 1998-12-15 | Ciba Vision Corporation | Extended wear ophthalmic lens |
US5776999B1 (en) | 1994-09-06 | 2000-11-21 | Ciba Vision Corp | Methods of using and screening extended wear opthalmic lenses |
US5789461B1 (en) | 1994-09-06 | 2000-11-21 | Ciba Vision Corp | Methods of forming an extended wear ophthalmic lens having a hydrophilic surface |
US5760100B1 (en) | 1994-09-06 | 2000-11-14 | Ciba Vision Corp | Extended wear ophthalmic lens |
US5710302A (en) | 1995-12-07 | 1998-01-20 | Bausch & Lomb Incorporated | Monomeric units useful for reducing the modules of silicone hydrogels |
US5817924A (en) | 1998-01-21 | 1998-10-06 | Modern Controls, Inc. | Method and apparatus for measuring oxygen transmission through contact lenses |
US5998498A (en) | 1998-03-02 | 1999-12-07 | Johnson & Johnson Vision Products, Inc. | Soft contact lenses |
US6087415A (en) | 1998-06-11 | 2000-07-11 | Johnson & Johnson Vision Care, Inc. | Biomedical devices with hydrophilic coatings |
JP2000016905A (ja) | 1998-07-01 | 2000-01-18 | Tokuriki Kagaku Kenkyusho:Kk | 抗菌抗かび剤および抗菌抗かび材料 |
Also Published As
Publication number | Publication date |
---|---|
BRPI0718298A2 (pt) | 2013-12-03 |
KR20090094816A (ko) | 2009-09-08 |
TW200837342A (en) | 2008-09-16 |
HK1138640A1 (zh) | 2010-08-27 |
AR063753A1 (es) | 2009-02-18 |
US7793535B2 (en) | 2010-09-14 |
US20100300182A1 (en) | 2010-12-02 |
EP2078186B1 (en) | 2014-05-07 |
RU2009120559A (ru) | 2010-12-10 |
CA2668296C (en) | 2015-12-29 |
CN101573604B (zh) | 2013-12-04 |
CA2668296A1 (en) | 2008-05-08 |
RU2443999C2 (ru) | 2012-02-27 |
HK1133297A1 (zh) | 2010-03-19 |
EP2078186A2 (en) | 2009-07-15 |
TWI460417B (zh) | 2014-11-11 |
CN101573604A (zh) | 2009-11-04 |
AU2007313797A1 (en) | 2008-05-08 |
JP2010508562A (ja) | 2010-03-18 |
WO2008055047A3 (en) | 2008-06-26 |
US20080100795A1 (en) | 2008-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20100300182A1 (en) | Devices and methods to simulate an ocular environment | |
US10045975B2 (en) | Methods and ophthalmic devices used in the treatment of ocular allergies | |
CN101573102B (zh) | 测试眼部药物递送系统扩散率的方法和装置 | |
AU2007305205B2 (en) | Methods and ophthalmic devices used in the treatment of ocular allergies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780048959.0 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07854430 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007313797 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2009535401 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2668296 Country of ref document: CA Ref document number: 1625/KOLNP/2009 Country of ref document: IN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007854430 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2007313797 Country of ref document: AU Date of ref document: 20071026 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020097011210 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2009120559 Country of ref document: RU Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: PI0718298 Country of ref document: BR Kind code of ref document: A2 Effective date: 20090430 |